INT100664

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.10
First Reported 2002
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 13
Disease Relevance 9.77
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (MKI67) nucleolus (MKI67) nucleus (MKI67)
intracellular (MKI67) cell cycle (MKI67) DNA metabolic process (MKI67)
Anatomy Link Frequency
neuronal 1
stroma 1
SK-OV-3 1
glands 1
MKI67 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 18 50.00 Quite Low
cINOD 2 50.00 Quite Low
transdermal 1 42.68 Quite Low
imagery 12 34.32 Quite Low
aspirin 2 10.00 Low Low
COX2 1 10.00 Low Low
dexamethasone 2 7.60 Low Low
antagonist 29 5.00 Very Low Very Low Very Low
cva 23 5.00 Very Low Very Low Very Low
headache 20 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 668 100.00 Very High Very High Very High
Ganglion Cysts 70 100.00 Very High Very High Very High
Diarrhoea 1 98.52 Very High Very High Very High
Exanthema 14 97.96 Very High Very High Very High
Ganglioglioma 84 96.64 Very High Very High Very High
Breast Cancer 232 96.48 Very High Very High Very High
Rhinitis 8 93.68 High High
Arthralgia 10 93.28 High High
Breast Disease 3 90.76 High High
Oligodendroglioma 114 90.64 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
A significant decrease in Ki-67 compared with controls in the OVCAR-3 (P = 0.005) and SK-OV-3 (P = 0.007) cell lines after treatment with the COX-2 inhibitor was observed.
Negative_regulation (decrease) of Ki-67 in SK-OV-3
1) Confidence 0.10 Published 2002 Journal Clin. Cancer Res. Section Body Doc Link 11801560 Disease Relevance 0.07 Pain Relevance 0
However, all doses of asoprisnil significantly suppressed the proliferation markers Ki-67 (Figure 5) and Phospho-H3 (Figure 6) in the endometrial glands, and the two higher doses caused significant shrinkage in endometrial thickness (Figures 7, 8) without inducing progestational effects such as glandular sacculation and secretion.
Negative_regulation (suppressed) of Ki-67 in glands
2) Confidence 0.04 Published 2006 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1775068 Disease Relevance 0.06 Pain Relevance 0
Letrozole significantly decreased the geometric mean Ki67 level in HER2 FISH-negative tumors (from 6.25 [95% CI 5.16, 7.58%] to 0.68% [95% CI 0.53, 0.87%]; P = 0.0001), but the decrease in HER2 FISH-positive tumors was blunted (from 14.73 [95% CI 9.67, 22.44%] to 8.1% [95% CI 4.16, 15.75%]; not significant).
Negative_regulation (decreased) of Ki67 associated with cancer
3) Confidence 0.03 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001223 Disease Relevance 0.84 Pain Relevance 0
Letrozole inhibited tumor proliferation, measured by the biomarker Ki67, to a greater extent than tamoxifen (reduction in geometric mean Ki67 level 87 vs. 75%, respectively; P = 0.0009).
Negative_regulation (reduction) of Ki67 associated with cancer
4) Confidence 0.03 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001223 Disease Relevance 0.84 Pain Relevance 0
Erlotinib inhibited tumour cell proliferation (Ki-67), and phosphorylation of EGFR and HER2.
Negative_regulation (inhibited) of Ki-67 associated with cancer
5) Confidence 0.03 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2575526 Disease Relevance 1.32 Pain Relevance 0
More recently, it was found that HER2 FISH-positive tumors showed higher histologic grade (P = 0.009), higher pretreatment Ki67 (P = 0.005), and less Ki67 suppression after letrozole when compared with HER2 FISH-negative tumors (P = 0.0001) [40].
Negative_regulation (suppression) of Ki67 associated with cancer
6) Confidence 0.02 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001223 Disease Relevance 0.87 Pain Relevance 0
However, negative staining in both stroma and cancer after treatment was strongly associated with fewer cell cycle CR and smaller Ki67 declines with letrozole (but not tamoxifen) treatment [48].


Negative_regulation (declines) of Ki67 in stroma associated with cancer
7) Confidence 0.02 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001223 Disease Relevance 0.59 Pain Relevance 0
More recently, it was found that HER2 FISH-positive tumors showed higher histologic grade (P = 0.009), higher pretreatment Ki67 (P = 0.005), and less Ki67 suppression after letrozole when compared with HER2 FISH-negative tumors (P = 0.0001) [40].
Negative_regulation (suppression) of Ki67 associated with cancer
8) Confidence 0.02 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001223 Disease Relevance 0.86 Pain Relevance 0
Letrozole was shown to be significantly more effective than tamoxifen in the inhibition of ER+ tumor proliferation, since letrozole produced a greater reduction in levels of the proliferation biomarker Ki67 [38].
Negative_regulation (reduction) of Ki67 associated with cancer
9) Confidence 0.02 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001223 Disease Relevance 0.66 Pain Relevance 0
The GGLF included enlarged dysmorphic and occasionally binucleate ganglion cells, Nissl substance, expression of neuronal antigens, GFAP-positive astrocytic elements, and low Ki-67 labeling indices.
Negative_regulation (binucleate) of Ki-67 in neuronal associated with ganglion cysts
10) Confidence 0.02 Published 2010 Journal Acta Neuropathol Section Abstract Doc Link PMC2892612 Disease Relevance 1.24 Pain Relevance 0
The Ki-67 labeling index was mostly low, but focally reached up to 12% in the oligodendroglial component.
Negative_regulation (reached) of Ki-67
11) Confidence 0.02 Published 2010 Journal Acta Neuropathol Section Body Doc Link PMC2892612 Disease Relevance 1.12 Pain Relevance 0
Fig. 3A box plot of before and after treatment Ki67 values in the estrogen-receptor-positive, human epidermal growth factor receptor (HER) 1/2+ subset.
Negative_regulation (plot) of Ki67
12) Confidence 0.02 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001223 Disease Relevance 0.80 Pain Relevance 0
An approximate two-thirds reduction in breast tissue proliferation (Ki-67) was observed after 6 months of letrozole.
Negative_regulation (reduction) of Ki-67
13) Confidence 0.01 Published 2007 Journal International Journal of Clinical Practice Section Body Doc Link PMC2228389 Disease Relevance 0.51 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox